Analyse of Diagnosis Value of Keloid on 68Ga-RGD PET-CT
ConditionKeloid
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorPeking Union Medical College Hospital
About this trial
Keloids are often described as benign dermal fibroproliferative lesions characterized by increased growth beyond the boundaries of the original wound margin.Fibroblasts are considered to be the key cellular mediators of fibrogenesis in keloid scars. Thus this prospective study is going to investigate whether 68Ga-RGD PET/CT may provide evidence for diagnosis and evaluate the effectiveness of treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Design model
Single group
Treatments tested in this trial
68Ga-RGD
DrugIntravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga- FAPI will be used to image lesions of keloid by PET/ CT.
Treatment groups
30 Participants
are divided into 1 treatment groupGroup A: 68Ga-RGD PET/CTExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Correlation with clinical symptoms, laboratory tests
The clinical assessment of keloids commonly includes the Vancouver Scar Scale for objective scar evaluation, along with laboratory inflammatory markers such as complete blood count (CBC), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).
Time frame
1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov